Inicio / De Interés / Artículos Científicos / Low-Dose Oral Isotretinoin for Moderate to Severe Seborrhea and Seborrheic Dermatitis: A Randomized Comparative Trial

Low-Dose Oral Isotretinoin for Moderate to Severe Seborrhea and Seborrheic Dermatitis: A Randomized Comparative Trial

Int. J. Dermatol 2016 Oct 25;[EPub Ahead of Print], C de Souza Leão Kamamoto, A Sanudo, KM Hassun, E Bagatin

Abstract

BACKGROUND: The efficacy of low-dose oral isotretinoin in the treatment of seborrhea and seborrheic dermatitis has been poorly investigated in randomized studies.
OBJECTIVES: This study was designed to determine the efficacy and safety of low-dose oral isotretinoin in the treatment of moderate to severe seborrhea and seborrheic dermatitis on the scalp and/or face.
METHODS: A randomized, comparative clinical trial, using two groups, was conducted over 6 months. Patients in Group ISO were treated with isotretinoin 10 mg every other day. In Group X, patients received antiseborrheic topical treatment. Patient opinion, investigator assessment, scalp pruritus, sebum production, and quality of life (QoL) comprised the efficacy outcomes.
RESULTS: The intention-to-treat population comprised a total of 45 patients with mean ± standard deviation ages of 28.7 ± 5.8 years in Group ISO and 29.8 ± 6.5 years in Group X. The rate of sebum production significantly decreased in Group ISO. Patient opinion, investigator, and QoL assessments improved in both groups.
CONCLUSIONS: Low-dose oral isotretinoin can be a therapeutic modality for moderate to severe seborrhea and seborrheic dermatitis.

Acerca de PIEL-L

Mesa de redacción de Piel Latinoamericana. Donde recibimos casos, aportes e información de interés para la comunidad latinoamericana dermatólogica

Deja un comentario

Para casos clínicos, sólo se publicarán comentarios de Suscriptores Especialistas de Salud registrados en nuestra base de datos.

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

 

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies